TGFB1 and colitis: There is also evidence that anti-fibrogenic drugs used for the treatment of fibrotic diseases (i.e., pirfenidone) suppress intestinal fibrosis in a DSS-induced colitis model by inhibiting TGF-β signaling [80,81].